尿路感染症(UTI)治療薬市場:パイプライン分析・治験・特許・指定・協力・動向

P&S Market Researchが発行した調査報告書(PSM804028)
◆英語タイトル:Urinary Tract Infections (UTIs) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
◆商品コード:PSM804028
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2018年2月
◆ページ数:145
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD3,250 ⇒換算¥357,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,750 ⇒換算¥852,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Urinary tract infection (UTI) refer to a common bacterial infection disease, that occurs in either a community or healthcare setting. Clinically, UTIs are categorized as uncomplicated and complicated. Uncomplicated UTIs typically occur in a healthy adult non-pregnant woman and have no structural or neurological urinary tract abnormalities; these infections are differentiated into cystitis and pyelonephritis.
UTIs are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. Gram-negative rod Escherichia coli is the most common cause of UTIs in all settings and is transmitted by person-to-person direct contact and the fecal-oral route. The study analyzed that UTIs therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.

Pipeline Insights

According to the research findings, a majority of the drug candidates for the treatment of UTIs are being developed as small molecules. It has been observed that the drugs that are being developed as small molecules are easy to manufacture with high production rate.

Significant growth due to various technological advancements

It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies and these drug candidates have further shown positive efficacy in the clinical stage of development. For instance, MULTIPHORE Drug Design platform developed by Talon Pharmaceuticals Inc., specifies the complexity of the disease in nature. The above-mentioned technology is designed to identify the drug that interacts with multiple disease target through careful incorporation of multiple pharmacophores into a single molecule or through unique combination of different mechanisms of action implicated in the disease state.

The pipeline has more drug candidates being developed as combination therapies

The companies involved in the UTIs therapeutic pipeline are developing various drug candidates as combination therapies, that have several advantages such as, improved medication compliance by decreasing the pill burden of patients, increased efficacy, and reduced side effects and cost. For instance, C-Scape, a Phase I drug candidate by Achaogen Inc. is a combination of ceftibuten and clavulanate, that are small molecules obtained from the synthetic source. Both ceftibuten and clavulanate act by different mechanism of action but give synergistic effects. Ceftibuten acts as cell wall synthesis inhibitor and, clavulanate acts as beta-lactamase inhibitor.

Some of the key players involved in the development of UTIs therapeutics pipeline include Achaogen Inc., AmpliPhi Biosciences Corporation, and Iterum Therapeutics Limited.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Sign & Symptoms

4.3 Epidemiology

4.4 Diagnosis

4.5 Prevention and Treatment

4.6 Key Drivers

4.6.1 Combination Therapies for Treating UTIs

4.6.2 Technological Advancements

4.7 Key Barriers

4.7.1 Risk Factors Involved in the Treatment of UTIs

4.8 UTIs Therapeutics Pipeline Analysis

4.8.1 Pipeline Analysis by Phase

4.8.2 Pipeline Analysis by Molecule Type

4.8.3 Pipeline Analysis by Route of Administration

4.8.4 Pipeline Analysis by Company

Chapter 5. UTIs Therapeutics Pipeline Analysis by Phase (2018)

5.1 Filed

5.1.1 Plazomicin

5.1.1.1 Clinical trial

5.1.1.2 Results

5.1.1.3 Strategic development

5.2 Phase III (Expanded Access)

5.2.1 AB-PA01

5.2.1.1 Pre-Clinical studies

5.3 Phase III

5.3.1 MK-7655

5.3.1.1 Clinical trial

5.3.2 XXXX

5.3.2.1 Clinical trial

5.3.3 XXXX

5.3.3.1 Clinical trial

5.3.3.2 Clinical results

5.3.3.3 Strategic development

5.3.4 XXXX

5.3.4.1 Clinical trial

5.3.4.2 Strategic development

5.3.5 XXXX

5.3.5.1 Clinical trial

5.3.5.2 Strategic development

5.3.6 XXXX

5.3.6.1 Clinical trial

5.3.6.2 Clinical trial results

5.3.6.3 Strategic development

5.4 Phase II/III

5.4.1 LACTIN-V

5.4.1.1 Clinical trial

5.4.1.2 Clinical result

5.5 Phase II

5.5.1 XXXX

5.5.1.1 Clinical trials

5.5.1.2 Clinical results

5.5.1.3 Strategic development

5.5.2 XXXX

5.5.2.1 Clinical trials

5.5.2.2 Strategic development

5.5.3 XXXX

5.5.3.1 Clinical trials

5.5.3.2 Clinical trial results

5.5.3.3 Strategic development

5.5.4 XXXX

5.5.4.1 Clinical trials

5.5.5 XXXX

5.5.5.1 Pre-Clinical results

5.5.5.2 Clinical trials

5.5.5.3 Clinical trial results

5.5.5.4 Strategic development

5.6 Phase I

5.6.1 XXXX

5.6.2 XXXX

5.6.2.1 Strategic development

5.6.3 XXXX

5.6.3.1 Pre-Clinical studies

5.6.3.2 Clinical trials

5.6.3.3 Strategic development

5.6.3.4 Technology

5.6.4 XXXX

5.6.4.1 Clinical studies

5.6.4.2 Safety results

5.6.4.3 Pharmacokinetics results

5.6.4.4 Final Results

5.6.5 XXXX

5.6.6 XXXX

5.6.6.1 Clinical trials

5.6.6.2 Strategic development

5.6.6.3 Technology

5.6.7 XXXX

5.6.7.1 Clinical trials

5.6.7.2 Clinical results

5.6.7.3 Strategic development

5.6.8 XXXX

5.6.8.1 Clinical trials

5.6.8.2 Clinical trial results

5.6.8.3 Strategic development

5.6.9 XXXX

5.6.9.1 Clinical trials

5.6.9.2 Strategic development

5.7 IND

5.7.1 XXXX

5.7.1.1 Pre-Clinical studies

5.7.1.2 Strategic development

5.8 Pre-Clinical

5.8.1 XXXX

5.8.1.1 Pre-Clinical studies

5.8.2 XXXX

5.8.2.1 Pre-Clinical studies

5.8.3 XXXX

5.8.3.1 Strategic development

5.8.4 XXXX

5.8.5 XXXX

5.8.5.1 Pre-Clinical Results

5.8.6 XXXX

5.8.6.1 Strategic Development

5.8.7 XXXX

5.8.8 XXXX

5.8.8.1 Strategic development

5.8.9 XXXX

5.8.9.1 Strategic development

5.8.10 XXXX

5.9 Discovery

5.9.1 XXXX

5.9.2 XXXX

5.9.2.1 Technology

5.9.3 XXXX

5.9.4 XXXX

5.9.4.1 Strategic development

5.9.4.2 Technology

5.9.5 XXXX

5.1 Unknown

5.10.1 XXXX

5.10.1.1 Clinical trials

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for UTIs Therapeutics Pipeline

7.2 SWOT Analysis of UTIs Therapeutics Pipeline

Chapter 8. Company Profiles

8.1 Rebiotix Inc.

8.1.1 Business Overview

8.1.2 Products and Service Offerings

8.2 Company 2

8.2.1 Business Overview

8.2.2 Products and Service Offerings

8.3 Company 3

8.3.1 Business Overview

8.3.2 Products and Service Offerings

8.4 Company 4

8.4.1 Business Overview

8.4.2 Products and Service Offerings

8.5 Company 5

8.5.1 Business Overview

8.5.2 Products and Service Offerings

8.6 Company 6

8.6.1 Business Overview

8.6.2 Products and Service Offerings

8.7 Company 7

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 Company 8

8.8.1 Business Overview

8.8.2 Product and Service Offerings

8.9 Company 9

8.9.1 Business overview

8.9.2 Product and Service Offerings

8.10 Company 10

8.10.1 Business Overview

8.10.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

List of Tables

TABLE 1 UTIs SYNDROMES: SIGNS, AND SYMPTOMS

TABLE 2 PIPELINE ANALYSIS OF UTIs THERAPEUTISCS, BY COMPANY (2018)

TABLE 3 DESCRIPTION OF PLAZOMICIN

TABLE 4 CLINICAL TRIALS OF PLAZOMICIN

TABLE 5 DETAILS OF PRIMARY END POINT 1

TABLE 6 DETAILS OF PRIMARY END POINT 2

TABLE 7 DESCRIPTION OF AB-PA01

TABLE 8 DESCRIPTION OF MK-7655

TABLE 9 CLINICAL TRIALS OF MK-7655

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 CLINICAL TRIALS OF XXXX

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 CLINICAL TRIALS OF XXXX

TABLE 14 DESCRIPTION OF XXXX

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 CLINICAL TRIALS OF XXXX

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 CLINICAL TRIALS OF XXXX

TABLE 19 DESCRIPTION OF LACTIN-V

TABLE 20 CLINICAL TRIALS OF LACTIN-V

TABLE 21 DESCRIPTION OF XXXX

TABLE 22 CLINICAL TRIALS OF XXXX

TABLE 23 DESCRIPTION OF XXXX

TABLE 24 CLINICAL TRIALS OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 CLINICAL TRIALS OF XXXX

TABLE 27 DETAILS OF ENDPOINT 1

TABLE 28 DETAILS OF ENDPOINT 2

TABLE 29 DETAILS OF ENDPOINT 3

TABLE 30 DESCRIPTION OF XXXX

TABLE 31 CLINICAL TRIALS OF XXXX

TABLE 32 DESCRIPTION OF XXXX

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 DESCRIPTION OF XXXX

TABLE 36 DESCRIPTION OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 DESCRIPTION OF XXXX

TABLE 39 CLINICAL TRIALS OF XXXX

TABLE 40 DESCRIPTION OF XXXX

TABLE 41 CLINICAL TRIALS OF XXXX

TABLE 42 DESCRIPTION OF XXXX

TABLE 43 CLINICAL TRIALS OF XXXX

TABLE 44 DESCRIPTION OF XXXX

TABLE 45 CLINICAL TRIALS OF XXXX

TABLE 46 DESCRIPTION OF XXXX

TABLE 47 DESCRIPTION OF XXXX

TABLE 48 DESCRIPTION OF XXXX

TABLE 49 DESCRIPTION OF XXXX

TABLE 50 DESCRIPTION OF XXXX

TABLE 51 DESCRIPTION OF XXXX

TABLE 52 DESCRIPTION OF XXXX

TABLE 53 DESCRIPTION OF XXXX

TABLE 54 DESCRIPTION OF XXXX

TABLE 55 DESCRIPTION OF XXXX

TABLE 56 DESCRIPTION OF XXXX

TABLE 57 DESCRIPTION OF XXXX

TABLE 58 DESCRIPTION OF XXXX

TABLE 59 DESCRIPTION OF XXXX

TABLE 60 DESCRIPTION OF XXXX

TABLE 61 DESCRIPTION OF XXXX

TABLE 62 DESCRIPTION OF XXXX

TABLE 63 CLINICAL TRIALS OF XXXX

TABLE 64 REBIOTIX INC. – AT A GLANCE

TABLE 65 COMPANY 2 – AT A GLANCE

TABLE 66 COMPANY 3 – AT A GLANCE

TABLE 67 COMPANY 4 – AT A GLANCE

TABLE 68 COMPANY 5 – AT A GLANCE

TABLE 69 COMPANY 6 – AT A GLANCE

TABLE 70 COMPANY 7 – AT A GLANCE

TABLE 71 COMPANY 8 – AT A GLANCE

TABLE 72 COMPANY 9 – AT A GLANCE

TABLE 73 COMPANY 10 – AT A GLANCE

List of Figures

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: UTIs DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 5: UTIs PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6: UTIs PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 尿路感染症(UTI)治療薬市場:パイプライン分析・治験・特許・指定・協力・動向(Urinary Tract Infections (UTIs) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆